Baltimore/ Politics & Govt

Maryland Secures $3.5 Million From Indivior Over Opioid Marketing Claims

AI Assisted Icon
Published on November 17, 2026
Maryland Secures $3.5 Million From Indivior Over Opioid Marketing ClaimsSource: Adam Kutzko / Wikimedia Commons

Maryland has reached a finalized $3.5 million settlement with Indivior, the drug manufacturer accused of improperly marketing its opioid-use-disorder products and failing to monitor suspicious orders. The deal, announced by the Maryland Attorney General's office, sends more than $1.5 million in opioid abatement funds and $2 million worth of addiction-treatment medication to the state and its local subdivisions.

The settlement was entered as a consent judgment in the Circuit Court for Frederick County, according to a statement from oag.maryland.gov. As first reported by Eastern Shore Undercover, Maryland filed a complaint against Indivior on November 6, alleging the company improperly marketed its products and failed to monitor suspicious orders. Indivior makes, markets, and sells buprenorphine products, which are approved to treat opioid use disorder and can help people in recovery when paired with appropriate medical care and support.

What Maryland Says the Money Will Do

Both the cash settlement and the treatment medication will be used by Maryland and its subdivisions to provide additional treatment resources and continue fighting the opioid epidemic, per the same account from the attorney general's office. Attorney General Anthony G. Brown said drug manufacturers must be held accountable for irresponsibly marketing their products. The settlement delivers millions of dollars in treatment to Maryland communities and includes court-ordered injunctive terms for Indivior going forward.

Those injunctive terms set limits on Indivior's promotions. Under the agreement, Indivior must cut back some promotional activities, its promotions must be truthful and must not encourage misuse of its products, and the company cannot tie salesperson pay or discipline to the volume of opioid-use-disorder products sold.

How This Fits a Larger National Pattern

Maryland's deal follows a separate national settlement agreement, dated April 4, 2025, between Indivior and participating states, according to a document posted by the National Opioid Settlement. That agreement defines a global settlement amount of $83,537,683 and commits Indivior to providing settling states with settlement product valued at $140 million, paid out through four annual remediation payments. The agreement specifies that no less than 95% of Indivior's maximum amount of payments may be allocated toward opioid remediation over the full payment term, and it states that Indivior does not admit liability or wrongdoing.

It is not clear from available records how that national agreement's figures relate to Maryland's separate $3.5 million settlement. A 2024 report from Insurance Journal described an earlier $86 million settlement Indivior reached with 16 U.S. states, with funds meant to be used over five years for opioid addiction treatment, recovery, and prevention. That report said Indivior had been accused of improperly targeting sales to doctors running pill mills and failing to monitor suspicious orders, and noted at the time that a final settlement still had to be negotiated.

A History of Federal Scrutiny

Indivior's legal troubles with opioid marketing predate these state settlements. The U.S. Department of Health and Human Services Office of Inspector General has noted that Indivior Solutions, together with its parent companies Indivior Inc. and Indivior plc, agreed to pay a total of $600 million to resolve criminal and civil liability tied to the marketing of its opioid-addiction-treatment drug, according to the U.S. Department of Health and Human Services Office of Inspector General.

Overdose Trends Across Maryland

The settlement arrives as Maryland continues to track its opioid overdose crisis. Overdose death rates have shown signs of decline overall statewide, though the Maryland Department of Health has noted that disparities persist, with fatal overdoses among Black Marylanders in 2025 measuring 1.4 times higher than among white Marylanders, according to the Maryland Department of Health. Separately, the Office of Governor Wes Moore has said Overdose Response Programs across the state distributed a record number of naloxone doses, the medication used to reverse opioid overdoses, though the underlying figures were not detailed in that announcement.